Form 4: Altimmune Director Catherine Sohn Granted Stock Options

Altimmune, Inc. Director Catherine A. Sohn was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Summary

• Catherine A. Sohn, a Director of Altimmune, Inc. (ALT), was granted 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The transaction date for this grant was September 25, 2025.
• The options will vest in substantially equal monthly installments over 12 months, starting from September 25, 2025.
• Vesting is contingent upon Ms. Sohn's continued service to the company.
• The options have an expiration date of September 25, 2035.
• Following this transaction, Ms. Sohn beneficially owns 48,800 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally neutral but can be seen as slightly positive due to the alignment of interests. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options to Director Catherine A. Sohn aligns her interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over 12 months encourages continued service and commitment from the director.

Future Outlook

The stock options granted to Director Catherine A. Sohn will vest in substantially equal monthly installments over the 12 months following September 25, 2025, subject to her continued service. This indicates an expectation of her ongoing involvement with the company.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to attract and retain talent, and to align the interests of directors with those of shareholders. This filing reflects a standard compensation mechanism.

Comparison to Industry Standards

• This Form 4 reports a routine grant of stock options as part of director compensation. Without specific details on Altimmune's overall compensation philosophy or comparable director compensation packages from similar-sized biotech companies (e.g., Viking Therapeutics, Madrigal Pharmaceuticals, or other clinical-stage biotechs), a detailed assessment against global benchmarks is not possible from this filing alone. However, the structure of options with a vesting schedule is a standard industry practice.

Related Party Transactions

• The grant of 48,800 stock options to Catherine A. Sohn, a Director of Altimmune, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value creation.

Next Steps

• The stock options will begin vesting in substantially equal monthly installments over the 12 months following September 25, 2025.
• The reporting person must continue service through the applicable vesting dates to receive the shares.

Key Dates

Keywords

Altimmune, ALT, Form 4, stock options, insider transaction, Catherine Sohn, director compensation